Thierry Bernard,
Managing Director
|
03/15/24
|
Common Shares received through release of Performance Based Stock Units (“net share settlement”)
|
5,487
|
|
PDF
|
PDF
|
Roland Sackers,
Managing Director
|
03/15/24
|
Common Shares received through release of Performance Based Stock Units (“net share settlement”)
|
5,937
|
|
PDF
|
PDF
|
All Supervisory,
Board Directors2)
|
02/29/24 Grant
|
Restricted Stock Units
|
7,056
|
|
PDF
|
PDF
|
Thierry Bernard,
Managing Director
|
02/29/24 Grant
|
Performance Based Stock Units
|
128,535
|
|
PDF
|
PDF
|
Roland Sackers,
Managing Director
|
02/29/24 Grant
|
Performance Based Stock Units
|
74,439
|
|
PDF
|
PDF
|
Lawrence A. Rosen,
Supervisory Director
|
02/28/24
|
Common Shares
received through release of Restricted Stock Units (“net share settlement”)
|
2,959
|
|
PDF
|
PDF
|
Metin Colpan,
Supervisory Director
|
02/28/24
|
Common Shares
received through release of Restricted Stock Units (“net share settlement”)
|
2,813
|
|
PDF
|
PDF
|
Ross L. Levine,
Supervisory Director
|
02/28/24
|
Common Shares
received through release of Restricted Stock Units (“net share settlement”)
|
2,560
|
|
PDF
|
PDF
|
Elaine R. Mardis,
Supervisory Director
|
02/28/24
|
Common Shares
received through release of Restricted Stock Units (“net share settlement”)
|
2,683
|
|
PDF
|
PDF
|
Elizabeth E. Tallett,
Supervisory Director
|
02/28/24
|
Common Shares
received through release of Restricted Stock Units (“net share settlement”)
|
2,987
|
|
PDF
|
PDF
|
Thierry Bernard,
Managing Director
|
02/28/24
|
Common Shares
received through release of Restricted Stock Units (“net share settlement”)
|
6,138
|
|
PDF
|
PDF
|
Roland Sackers,
Managing Director
|
02/28/24
|
Common Shares
received through release of Restricted Stock Units (“net share settlement”)
|
6,061
|
|
PDF
|
PDF
|
Lawrence A. Rosen,
Supervisory Director
|
02/26/24
|
Common Shares
received through release of Restricted Stock Units (“net share settlement”)
|
1,552
|
|
PDF
|
PDF
|
Metin Colpan,
Supervisory Director
|
02/26/24
|
Common Shares
received through release of Restricted Stock Units (“net share settlement”)
|
1,503
|
|
PDF
|
PDF
|
Toralf Haag,
Supervisory Director
|
02/26/24
|
Common Shares
received through release of Restricted Stock Units (“net share settlement”)
|
1,945
|
|
PDF
|
PDF
|
Ross L. Levine,
Supervisory Director
|
02/26/24
|
Common Shares
received through release of Restricted Stock Units (“net share settlement”)
|
1,385
|
|
PDF
|
PDF
|
Elaine R. Mardis,
Supervisory Director
|
02/26/24
|
Common Shares
received through release of Restricted Stock Units (“net share settlement”)
|
1,404
|
|
PDF
|
PDF
|
Elizabeth E. Tallett,
Supervisory Director
|
02/26/24
|
Common Shares
received through release of Restricted Stock Units (“net share settlement”)
|
1,577
|
|
PDF
|
PDF
|
Thierry Bernard,
Managing Director
|
02/21/24
|
Common Shares
received through release of Performance Based Stock Units (“net share settlement”)
|
11,048
|
-
|
PDF
|
PDF
|
Roland Sackers,
Managing Director
|
02/21/24
|
Common Shares
received through release of Performance Based Stock Units (“net share settlement”)
|
33,898
|
-
|
PDF
|
PDF
|
Thierry Bernard,
Managing Director
|
02/15/24
|
Common Shares
received through release of Performance Based Stock Units (“net share settlement”)
|
220
|
-
|
PDF
|
PDF
|
Roland Sackers,
Managing Director
|
02/15/24
|
Common Shares
received through release of Performance Based Stock Units (“net share settlement”)
|
1,589
|
-
|
PDF
|
PDF
|
Lawrence A. Rosen,
Supervisory Director
|
01/29/24
|
Common Shares
(following the terms of the synthetic share repurchase by QIAGEN N.V., every 25 issued QIAGEN shares
were consolidated into 24.25 QIAGEN shares)
|
322
|
-
|
PDF
|
PDF
|
Metin Colpan,
Supervisory Director
|
01/29/24
|
Common Shares
(following the terms of the synthetic share repurchase by QIAGEN N.V., every 25 issued QIAGEN shares
were consolidated into 24.25 QIAGEN shares)
|
12,710
|
-
|
PDF
|
PDF
|
Toralf Haag,
Supervisory Director
|
01/29/24
|
Common Shares
(following the terms of the synthetic share repurchase by QIAGEN N.V., every 25 issued QIAGEN shares
were consolidated into 24.25 QIAGEN shares)
|
21
|
-
|
PDF
|
PDF
|
Ross L. Levine,
Supervisory Director
|
01/29/24
|
Common Shares
(following the terms of the synthetic share repurchase by QIAGEN N.V., every 25 issued QIAGEN shares
were consolidated into 24.25 QIAGEN shares)
|
396
|
-
|
PDF
|
PDF
|
Elizabeth E.Tallett,
Supervisory Director
|
01/29/24
|
Common Shares
(following the terms of the synthetic share repurchase by QIAGEN N.V., every 25 issued QIAGEN shares
were consolidated into 24.25 QIAGEN shares)
|
1,363
|
-
|
PDF
|
PDF
|
Stephen H. Rusckowski,
Supervisory Director
|
01/29/24
|
Common Shares
(following the terms of the synthetic share repurchase by QIAGEN N.V., every 25 issued QIAGEN shares
were consolidated into 24.25 QIAGEN shares)
|
1
|
-
|
PDF
|
PDF
|
Thierry Bernard, Managing Director
|
01/29/24
|
Common Shares
(following the terms of the synthetic share repurchase by QIAGEN N.V., every 25 issued QIAGEN shares
were consolidated into 24.25 QIAGEN shares)
|
5,651
|
-
|
PDF
|
PDF
|
Roland Sackers, Managing Director
|
01/29/24
|
Common Shares
(following the terms of the synthetic share repurchase by QIAGEN N.V., every 25 issued QIAGEN shares
were consolidated into 24.25 QIAGEN shares)
|
7,623
|
-
|
PDF
|
PDF
|